Print

OncoMethylome Sciences S.A. to Perform MGMT Testing in Roche (RHHBY) Phase III Study of Avastin for Glioblastoma  
1/13/2010 10:13:50 AM

Liege (Belgium) - January 6, 2010, 8:00 AM CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has entered into an agreement with F. Hoffmann-La Roche Ltd., of Basel Switzerland, for MGMT gene promoter methylation testing in a Phase III clinical trial for the use of Avastin in newly diagnosed (glioblastoma [GBM]) brain tumors.
//-->